Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Journal of Clinical Neuromuscular Disease ; 23(1 SUPPL):S5, 2022.
Article in English | EMBASE | ID: covidwho-1766670


Background: Till date, more than 49 million people have been affected by COVID 19. There are special concerns with regards to myasthenia gravis (MG) patients one is immune suppression increasing their susceptibility to infection and second infections exacerbating MG. We describe our experience with 17 MG patients who had COVID 19 and their outcomes. Methods: Seventeen patients with MG who developed COVID 19 were identified from our database at Houston Methodist Hospital. Results: Out of the 17, 15 patients had generalized MG and 2 patients had ocular MG. Twelve patients (70%) were hospitalized. Four patients (23%) died. Four patients recovered with residual COVID 19 related complications. Nine of the patients were on more than one immune suppressant medication. Seven patients (41%) had MG exacerbation. The type of immune suppressants and steroids did not seem to affect outcomes of COVID 19. Patients treated with intravenous immunoglobulin for MG exacerbation had variable COVID 19 outcomes. Results: In our case series, 6 patients experienced MG exacerbation. The outcomes with relation to COVID 19 were variable and being on immune suppressants did not confer any benefit. The outcomes were not affected by the type of immune suppression.

Neurology ; 96(15 SUPPL 1), 2021.
Article in English | EMBASE | ID: covidwho-1407798


Objective: To report neurological manifestations in patients with COVID-19Background: Early in the COVID-19 pandemic, data on neurologic manifestations of the novel virus was scarce. Over time, increasing evidence has emerged that COVID-19 affects the nervous system both centrally and peripherally although the exact prevalence and mechanism of action remain unknown. A few large-scale case series in the literature, most originating from China with one recent series from the United States, have evaluated neurologic complications in this patient population. Our case series of 100 COVID-19 patients aims to determine neurological manifestations along with their prevalence and potential risk factors. Our case series will be among one of the largest in the United States. We present an initial subgroup of 10 patients in this abstract. Design/Methods: Chart review of 100 COVID-19 patients at a tertiary care center in Houston, Texas along with literature review was performed. Results: Neurologic manifestations among this subgroup of patients included encephalopathy (5), headaches (2), bilateral internal carotid dissection (1), ischemic stroke (3), intracranial hemorrhage (1), cerebral microhemorrhages (1), status epilepticus (1), acute inflammatory demyelinating polyradiculoneuropathy (1), and brachial plexopathy (1). Conclusions: We have documented both common and rare neurologic presentations associated with COVID-19. A review of the entire cohort of 100 patients will be subsequently performed with regards to the spectrum of symptoms, their prevalence, and potential risk factors. With the continuation of the pandemic and high infection rate, knowledge of associated neurologic manifestations will aid not only in early diagnosis and appropriate treatment of newly diagnosed but also management of post-COVID-19 patients.